Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles.
- Author:
Han GUAN
1
;
Zhi-Xin LING
2
;
Fang FANG
3
;
Li-Kai MAO
4
;
Zong-Hao YOU
2
;
Can WANG
2
;
Shu-Qiu CHEN
5
;
Bin XU
5
;
Ming CHEN
5
Author Information
1. Department of Urology, The First Hospital of Bengbu Medical College,Bengbu Medical College, Bengbu, Anhui 233000, China.
2. Graduate School of Medical College,Southeast University, Nanjing, Jiangsu 210009, China..
3. Faculty of Immunology, Bengbu Medical College, Bengbu, Anhui 233000, China.
4. Graduate School, Bengbu Medical College, Bengbu, Anhui 233000, China.
5. Department of Urology, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, China.
- Publication Type:Journal Article
- Keywords:
C4-2B cell line;
LNCaP cell line;
enzalutamide resistance;
lncRNA;
mRNA;
prostate cancer
- MeSH:
Cell Line, Tumor;
drug effects;
Drug Resistance, Neoplasm;
Humans;
Male;
Phenylthiohydantoin;
analogs & derivatives;
pharmacology;
Prostatic Neoplasms;
drug therapy;
genetics;
pathology;
RNA, Long Noncoding;
metabolism;
RNA, Messenger;
metabolism;
RNA, Neoplasm;
metabolism;
Receptors, Androgen
- From:National Journal of Andrology
2018;24(2):116-121
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To establish enzalutamide-resistant human prostate cancer cell lines and screen out the lncRNA and mRNA expression profiles associated with enzalutamide resistance.
METHODS:Human prostate cancer cell lines LNCAP and C4-2B were cultured with 10 μmol/L enzalutamide for 6 months in vitro for the establishment of enzalutamide-resistant subclones LNCAP-ENZA and C4-2B-ENZA. The IC50 value and enzalutamide resistance index of each cell line were examined by MTT assay, the expressions of enzalutamide-related genes FL-AR, AR-V7 and HnRNPA1 were determined by Western blot, and the lncRNA and mRNA differential expressions of C4-2B and C4-2B-ENZA were detected by high-throughout lncRNA microarray.
RESULTS:Compared with LNCAP and C4-2B, the IC50 values of enzalutamide-resistant subclones LNCAP-ENZA (60.83 μmol/L) and C4-2B-ENZA (88.32 μmol/L) were increased significantly (P < 0.05) and the enzalutamide-resistance indexes of the LNCAP-ENZA and C4-2B-ENZA cells were 4.94 and 4.67, respectively. The expressions of AR-V7 and HnRNPA1 were markedly up-regulated in the LNCAP-ENZA and C4-2B-ENZA cells as compared with those in the LNCAP and C4-2B cells, but that of FL-AR showed no significant change. A total of 1 440 lncRNAs and 1 236 mRNAs were identified as differentially expressed in the C4-2B-ENZA cells.
CONCLUSIONS:Enzalutamide -resistant human prostate cancer cell subclones LNCAP-ENZA and C4-2B-ENZA were successfully established and enzalutamide resistance-associated lncRNA and mRNA were identified, which may provide some molecular evidence for the management of enzalutamide-resistant human prostate cancer.
